Please login to the form below

Not currently logged in
Email:
Password:

BMS and AZ gain approval for diabetes drug

The European Commission has granted marketing authorisation for Onglyza throughout the EU

The European Commission has granted marketing authorisation for the diabetes treatment Onglyza (saxagliptin) throughout the European Union(EU).

The once-daily 5 mg oral tablet dose is indicated in adult patients with type 2 diabetes mellitus in combination with other therapies (metformin, sulphonylurea, or thiazolidinedione) subject to certain criteria.

It was developed by Bristol-Myers Squibb(B-MS) and AstraZeneca(AZ) and is the first drug to be launched in Europe as part of the ongoing R&D collaboration between the two companies.

Béatrice Cazala, Bristol-Myers Squibb's president, Europe, and president, global commercialization, said: "The European Commission decision marks an important milestone in the alliance between Bristol-Myers Squibb and AstraZeneca."

Ulf Sather, AstraZeneca's regional vice president for Europe, commented: "Today's announcement is good news for those affected by type 2 diabetes and further demonstrates the commitment of AstraZeneca and Bristol-Myers Squibb to bring much needed options for the treatment of type 2 diabetes."

6th October 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

blood
‘How is your day?’
The initiative that shows how plasma protein therapies improve lives...
women
Advancing women in healthcare
Fostering the next generation of leaders...
The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....

Infographics